Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Beats Expectations By $0.01 EPS

Nuvectis Pharma (NASDAQ:NVCT) issued its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01, RTT News reports. During the same quarter in the previous year, the business earned ($0.37) earnings per share.

Nuvectis Pharma Stock Up 3.1 %

NASDAQ NVCT traded up $0.23 on Wednesday, reaching $7.66. The company had a trading volume of 124,705 shares, compared to its average volume of 102,579. The firm’s 50 day moving average price is $6.79 and its 200 day moving average price is $6.67. Nuvectis Pharma has a 12 month low of $5.85 and a 12 month high of $12.10. The stock has a market capitalization of $142.86 million, a PE ratio of -5.86 and a beta of 0.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research report on Tuesday, August 6th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.